Chiesi has bought Atopix Therapeutics and stepped into the fight for the next asthma blockbuster. Can it take on Novartis in the competition for what is expected to grow to a €24B market in 2024?
Chiesi is an Italian pharma with a strong focus on respiratory diseases. To strengthen its pipeline, the company has acquired the British Atopix Therapeutics for an amount that could exceed €75M if all milestones are met. With this deal, Chiesi incorporates OC459, a CRTh2 antagonist, to its pipeline. The drug candidate is currently in Phase II to treat eosinophilic asthma, a severe condition that affects 40% of the population.
